Previous 10 | Next 10 |
Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today t...
Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is delighted to announce the suc...
2024-04-22 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-22 08:16:12 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) Seeking Alpha’s Quant Rating on INmune Bio Historical earnings data for INmune Bio Financial information for INmune Bio Read the full articl...
Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today t...
2024-04-22 04:27:08 ET Summary INmune Bio is focused on developing drugs for neurology and cancer medicine. The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease. INMB's financial situation may require a cash raise by the ...
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage im...
2024-04-02 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-28 20:18:07 ET INmune Bio, Inc. (INMB) Q4 2023 Earnings Conference Call March 28, 2024, 04:30 PM ET Company Participants RJ Tesi - Chief Executive Officer David Moss - Chief Financial Officer Mark Lowdell - Chief Scientific Officer Conference Call P...
2024-03-28 16:06:23 ET More on INmune Bio INmune Bio: Caution Still Warranted But Upgrading To Hold Seeking Alpha’s Quant Rating on INmune Bio Historical earnings data for INmune Bio Financial information for INmune Bio Read the full article ...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...